S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
NASDAQ:IXHL

Incannex Healthcare (IXHL) Stock Forecast, Price & News

$1.14
-0.05 (-4.21%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.14
$1.20
50-Day Range
$1.11
$1.94
52-Week Range
$1.03
$4.87
Volume
3,162 shs
Average Volume
10,515 shs
Market Capitalization
$72.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IXHL stock logo

About Incannex Healthcare (NASDAQ:IXHL) Stock

Incannex Healthcare Limited, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Docklands, Australia.

IXHL Price History

IXHL Stock News Headlines

Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
Incannex preparing psilocybin therapy FDA IND application
Forget NVDA. Buy this A.I. stock instead
Dozens of 100% - 1,000% opportunities over the last decade have led to this one under-the-radar A.I. stock... MORE HERE...
Incannex CEO talks plans to redomicile to US
See More Headlines
Receive IXHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incannex Healthcare and its competitors with MarketBeat's FREE daily newsletter.

IXHL Company Calendar

Today
10/01/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IXHL
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$930,000.00
Book Value
$0.89 per share

Miscellaneous

Free Float
54,187,000
Market Cap
$72.15 million
Optionable
Not Optionable
Beta
1.18
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Joel Bradley Latham (Age 33)
    MD, CEO & Exec. Director
    Comp: $818.7k
  • Mr. Madhukar Bhalla FCIS (Age 64)
    CFO & Company Sec.
  • Mr. Lekhram Changoer M.Sc. (Age 56)
    Chief Technical Officer
  • Dr. Mark Bleackley
    Chief Scientific Officer, Head of Programs & Member of the Advisory Board
  • Mr. John Michailidis B.Sc.
    EMBA, M.A.I.C.D., Chief Exec. Officer of IncannexTM
  • Ms. Rosemarie Walsh
    VP of Clinical Operations & Member of the Advisory Board
  • Mr. Joseph Swan
    Head of Fin.













IXHL Stock - Frequently Asked Questions

How have IXHL shares performed in 2023?

Incannex Healthcare's stock was trading at $2.80 on January 1st, 2023. Since then, IXHL shares have decreased by 59.4% and is now trading at $1.1366.
View the best growth stocks for 2023 here
.

Are investors shorting Incannex Healthcare?

Incannex Healthcare saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 34,200 shares, a drop of 9.8% from the August 31st total of 37,900 shares. Based on an average trading volume of 123,700 shares, the short-interest ratio is currently 0.3 days.
View Incannex Healthcare's Short Interest
.

What is Incannex Healthcare's stock symbol?

Incannex Healthcare trades on the NASDAQ under the ticker symbol "IXHL."

How do I buy shares of Incannex Healthcare?

Shares of IXHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incannex Healthcare's stock price today?

One share of IXHL stock can currently be purchased for approximately $1.14.

How much money does Incannex Healthcare make?

Incannex Healthcare (NASDAQ:IXHL) has a market capitalization of $72.15 million and generates $930,000.00 in revenue each year.

How can I contact Incannex Healthcare?

Incannex Healthcare's mailing address is 13 Central Avenue, Melbourne, Victoria 3189. The official website for the company is impression.healthcare. The company can be reached via phone at 425-703-805 or via email at investors@incannex.com.

This page (NASDAQ:IXHL) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -